Patient support & resources
KIMMTRAK CONNECT® is here for you
You are not in this alone. If you and your doctor have decided KIMMTRAK is right for you, the KIMMTRAK CONNECT team is here. They can help you better understand your disease, know what to expect, and how to manage your treatment experience.
Every person with metastatic uveal melanoma (mUM) is unique. KIMMTRAK CONNECT provides services and support tailored to your specific needs.
You can call
KIMMTRAK CONNECT at
844-775-CARE (2273).
Available Monday-Friday, 9 AM-7 PM (EST)
Additionally, someone is available to help you 24/7.
KIMMTRAK CONNECT provides:
Your dedicated nurse case manager will help guide you through the services and support we offer.
We identify the options that are right for you. Once we understand your needs, we will help set you up with financial assistance.*
- * KIMMTRAK CONNECT is not insurance and does not guarantee product coverage or reimbursement.
Just tell us what you need, and we will try to help you manage your care. We may help coordinate infusion appointments once you and your physician choose a treatment location. We may also be able to assist you in locating affordable transportation to and from your treatment.
Watch this video to learn more about what KIMMTRAK CONNECT has to offer.
Resources
Videos
What is mUM?
HLA testing and why it’s important
How to talk to your doctor about KIMMTRAK
This video provides some important questions you may want to ask your doctor about treatment with KIMMTRAK.
What to expect when taking KIMMTRAK
For patient, doctor, and nurse perspectives on
treatment with KIMMTRAK, visit AACR.org.
Brochures
Advocacy groups
Below is a list of organizations involved in bringing attention to uveal melanoma. These organizations are not meant as an exhaustive list of all resources that may be available. Inclusion on the list does not imply Immunocore endorsement of a particular organization, nor has Immunocore independently validated the accuracy or content of any third-party informational materials.
Glossary
Chemotherapy (eg, dacarbazine): Treatment that uses chemicals to kill fast-growing cells (cancer cells) in your body.
Cytokine (sigh-toe-kine) release syndrome: Side effect of immunotherapy. It happens when a large number of cytokines, substances that help direct your body’s immune response, are released into the blood. Symptoms may include fever, tiredness or weakness, vomiting, chills, dizziness, light-headedness, headache, wheezing, and trouble breathing.
HLA-A*02:01 target: A target found on uveal melanoma tumor cells in those who are HLA-A*02:01 positive.
Human leukocyte (loo-ko-site) antigen (HLA): Set of genes that may help the immune system find and destroy cancer.
Immune system: A complex network of cells, tissues, organs, and the molecules they produce that work together to help your body fight infections and other disease.
Immunotherapy: A type of therapy that works along with your own immune system to help the body fight cancer and other diseases.
IV infusion: A way to give fluids, medicine, or nutrients directly into the bloodstream through a vein.
Median overall survival: A statistic that refers to how long patients survive after a particular treatment. It represents when half of the patients are expected to be alive.
Metastatic uveal (YOO-vee-uhl) melanoma: Occurs when the cancer that starts in the eye spreads to other parts of the body.
Phase 3 clinical trial: A clinical trial that compares new treatments with the best currently available treatment (standard of care).
Primary analysis: The first set of official results from a study.
Radiation therapy: A type of cancer treatment that uses high doses of radiation (energy) to kill cancer cells.
Statistical significance: A term that means a result is unlikely to be explained solely by chance or random factors.
T cell: A type of immune cell that helps your body fight foreign threats, like viruses and cancer.
Reminder: KIMMTRAK is not chemotherapy or radiation therapy—it is an immunotherapy that is designed to recruit and activate your T cells to fight uveal melanoma tumor cells.*
- * Normal skin cells could also be affected.
Indication
Important Safety Information Including Boxed Warning
KIMMTRAK is a prescription medicine used to treat HLA-A*02:01–positive adults with uveal melanoma that cannot be removed by surgery or has spread.
KIMMTRAK can cause serious side effects that can be severe or life threatening and usually happen within the first three infusions, including:
- Cytokine Release Syndrome (CRS). Symptoms of CRS may include:
Indication and Important Safety Information Including Boxed Warning
Usage
KIMMTRAK is a prescription medicine used to treat HLA-A*02:01–positive adults with uveal melanoma that cannot be removed by surgery or has spread.
Important Safety Information
What is the most important information I should know about KIMMTRAK?
KIMMTRAK can cause serious side effects that can be severe or life threatening and usually happen within the first three infusions, including:
- Cytokine Release Syndrome (CRS). Symptoms of CRS may include:
- fever
- tiredness or weakness
- vomiting
- chills
- nausea
- low blood pressure
- dizziness and light-headedness
- headache
- wheezing and trouble breathing
- rash
Tell your healthcare provider right away if you get any of these symptoms. Your healthcare provider will check for these problems during treatment with KIMMTRAK. Your healthcare provider may temporarily stop or completely stop your treatment with KIMMTRAK if you have severe side effects.
See "KIMMTRAK can cause other serious side effects" for more information.
Before receiving KIMMTRAK, tell your healthcare provider about all of your medical conditions, including if you:
- are pregnant or plan to become pregnant. KIMMTRAK may harm your unborn baby. Tell your healthcare provider if you become pregnant during treatment with KIMMTRAK.
For females who are able to become pregnant:
- Your healthcare provider should do a pregnancy test before you start treatment with KIMMTRAK.
- Use an effective form of birth control during treatment with KIMMTRAK and for at least 1 week after the last dose of KIMMTRAK.
- are breastfeeding or plan to breastfeed. It is not known if KIMMTRAK passes into your breast milk. Do not breastfeed during the treatment with KIMMTRAK and for at least 1 week after the last dose of KIMMTRAK.
Tell your healthcare provider about all medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.
KIMMTRAK can cause other serious side effects, including:
- Skin reactions. KIMMTRAK may cause skin reactions that require treatment. Tell your healthcare provider if you get symptoms of skin reactions—such as rash, itching, or skin swelling—that are severe and do not go away.
- Abnormal liver blood tests. Your healthcare provider will do blood tests to check your liver before you start KIMMTRAK and during treatment with KIMMTRAK. Tell your healthcare provider if you get symptoms of liver problems such as right-sided abdominal pain or yellowing of the skin or eyes.
The most common side effects of KIMMTRAK include:
- cytokine release syndrome (CRS)
- rash
- fever
- itching
- tiredness
- nausea
- chills
- stomach pain
- swelling
- low blood pressure (symptoms may include dizziness or light-headedness)
- dry skin
- headache
- vomiting
- abnormal liver blood tests
These are not all the side effects possible with KIMMTRAK.
Call your healthcare provider for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088 (1-800-332-1088).
Please read the accompanying Patient Information Leaflet before you receive KIMMTRAK and discuss any questions you have with your healthcare provider.
Please see KIMMTRAK Patient Information.
